Compare General Dynamics Corporation (GD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? General Dynamics Corporation trades at $392 (market cap $107.13B), while Vertex Pharmaceuticals Incorporated trades at $526.33 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and General Dynamics Corporation pays a 1.61% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| GD | VRTX | |
|---|---|---|
Market Cap | $107.13B | $132.79B |
Sector | Industrials | Health |
52-Week High | $395.97 | $529.59 |
52-Week Low | $312.53 | $374.46 |
Enterprise Value | $112.28B | $126.92B |
Dividend Yield | 1.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $392.05, up 1.33% today, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $4.24 versus $3.96 expected, with revenue growth across all segments. A $76.6 billion Navy contract awarded in July 2026 bolsters its backlog to $136.5 billion, providing visibility for future growth.
The stock offers upside to the $427.40 consensus price target, driven by defense spending tailwinds and operational execution. Risks include valuation at a 23.91 P/E and potential contract execution delays. Analyst sentiment is positive with 57% buy ratings, but overbought RSI levels near-term may limit gains.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
